The treatment of H. pylori remains a challenging clinical problem despite extensive research over the last 25 years. Levofloxacin (LVF) is safe and effective in first, second, and third line H. pylori eradication. Eradication rates were over 90% for the LVF based therapy. Conventional tablets or capsules have insufficient gastric residence time to treat H. pylori. Recently, gastroretentive systems for treating H. pylori have shown special interest. The prolongation of the local availability of the antibacterial agents has been reported to be an important factor to increase the effectiveness...